Impaired DICER1 function promotes stemness and metastasis in colon cancer

Oncogene

Volumn 33, Issue 30, 2014, Pages 4003-4015

  Iliou, M S ^a   Da Silva Diz, V ^a   Carmona, F J ^a   Ramalho Carvalho, J ^a   Heyn, H ^a   Villanueva, A ^a   Munoz P ^a   Esteller, M ^a,b,c  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DICER; DICER 1; MICRORNA 126; MICRORNA 200; MICRORNA 34A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE FUNCTION; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD44; ANTIGENS, NEOPLASM; CARCINOGENESIS; CELL ADHESION MOLECULES; COLONIC NEOPLASMS; DEAD-BOX RNA HELICASES; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MICRORNAS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; RIBONUCLEASE III; RNA INTERFERENCE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84904977196     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.398     Document Type: Article

References (89)

1. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009; 136: 215-233
2. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355 (Pubitemid 39265675)
3. Ventura A, Jacks T. MicroRNAs and cancer: Short RNAs go a long way. Cell 2009; 136: 586-591
4. Lujambio A, Lowe SW. The microcosmos of cancer. Nature 2012; 482: 347-355
5. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838 (Pubitemid 40839735)
6. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866 (Pubitemid 44629897)
7. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007; 67: 2456-2468 (Pubitemid 46548930)
8. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, Hammond SM. Extensive post-Transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 2006; 20: 2202-2207
9. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006; 5: 2220-2222 (Pubitemid 44546557)
10. Lopez-Serra P, Esteller M. DNA methylation-Associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 2012; 31: 1609-1622
11. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KMet al.Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43-50
12. Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet 2009; 41: 365-370
13. Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 2010; 18: 303-315
14. Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev 2009; 23: 2700-2704
15. Heravi-Moussavi A, Anglesio MS, Cheng SW, Senz J, Yang W, Prentice L et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 2012; 366: 234-242
16. Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005; 96: 111-115 (Pubitemid 40425386)
17. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008; 359: 2641-2650
18. Khoshnaw SM, Rakha EA, Abdel-Fatah TM, Nolan CC, Hodi Z, Macmillan DR et al. Loss of Dicer expression is associated with breast cancer progression and recurrence. Breast Cancer Res Treat 2012; 135: 403-413
19. Shu GS, Yang ZL, Liu DC. Immunohistochemical study of Dicer and Drosha expression in the benign and malignant lesions of gallbladder and their clinicopathological significances. Pathol Res Pract 2012; 208: 392-397
20. Wu D, Tao J, Xu B, Li P, Lu Q, Zhang W. Downregulation of Dicer, a component of the microRNA machinery, in bladder cancer. Mol Med Report 2012; 5: 695-699
21. Zhu DX, Fan L, Lu RN, Fang C, Shen WY, Zou ZJ et al. Downregulated Dicer expression predicts poor prognosis in chronic lymphocytic leukemia. Cancer Sci 2012; 103: 875-881
22. Faggad A, Kasajima A, Weichert W, Stenzinger A, Elwali NE, Dietel M et al. Downregulation of the microRNA processing enzyme Dicer is a prognostic factor in human colorectal cancer. Histopathology 2012; 61: 552-561
23. Guo X, Liao Q, Chen P, Li X, Xiong W, Ma J et al. The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2012; 138: 49-56
24. Stratmann J, Wang CJ, Gnosa S, Wallin A, Hinselwood D, Sun XF et al. Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients. BMC Cancer 2011; 11: 345
25. Grelier G, Voirin N, Ay AS, Cox DG, Chabaud S, Treilleux I et al. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer 2009; 101: 673-683
26. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S et al. A MicroRNA targeting dicer for metastasis control. Cell 2010; 141: 1195-1207
27. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ et al. Dicer is essential for mouse development. Nat Genet 2003; 35: 215-217 (Pubitemid 37363172)
28. Fukagawa T, Nogami M, Yoshikawa M, Ikeno M, Okazaki T, Takami Y et al. Dicer is essential for formation of the heterochromatin structure in vertebrate cells. Nat Cell Biol 2004; 6: 784-791 (Pubitemid 39144485)
29. Tang F, Kaneda M, O"Carroll D, Hajkova P, Barton SC, Sun YA et al. Maternal microRNAs are essential for mouse zygotic development. Genes Dev 2007; 21: 644-648 (Pubitemid 46440286)
30. Visvader JE. Cells of origin in cancer. Nature 2011; 469: 314-322
31. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz Jr LA, Sjoblom et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103: 3687-3692 (Pubitemid 43376616)
32. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115 (Pubitemid 46067311)
33. O"Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110 (Pubitemid 46067310)
34. Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 2008; 105: 13427-13432
35. Barker N, Ridgway RA, van Es JH. van De Wetering M, Begthel H, van Den Born M et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009; 457: 608-611
36. Kemper K, Prasetyanti PR, De Lau W, Rodermond H, Clevers H, Medema JP. Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells 2012; 30: 2378-2386
37. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158-10163 (Pubitemid 47175279)
38. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211-215
39. Henry JC, Park JK, Jiang J, Kim JH, Nagorney DM, Roberts LR et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2010; 403: 120-125
40. Wang CH, Lee DY, Deng Z, Jeyapalan Z, Lee SC, Kahai S et al. MicroRNA miR-328 regulates zonation morphogenesis by targeting CD44 expression. PLoS One 2008; 3: E2420
41. Jeyapalan Z, Deng Z, Shatseva T, Fang L, He C, Yang BB. Expression of CD44 3"-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res 2011; 39: 3026-3041
42. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10: 202-210 (Pubitemid 351194050)
43. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 1999; 154: 515-523 (Pubitemid 29094101)
44. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790 (Pubitemid 27136715)
45. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF. Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 1997; 94: 10330-10334 (Pubitemid 27407041)
46. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/ beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58: 1130-1134 (Pubitemid 28183198)
47. Mongroo PS, Rustgi AK. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther 2010; 10: 219-222
48. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271-1277
49. Negrini M, Calin GA. Breast cancer metastasis: A microRNA story. Breast Cancer Res 2008; 10: 203
50. Anton R, Chatterjee SS, Simundza J, Cowin P, Dasgupta R. A systematic screen for micro-RNAs regulating the canonical Wnt pathway. PLoS One 2011; 6: E26257
51. Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY et al. p53 and MicroRNA-34 Are Suppressors of Canonical Wnt Signaling. Sci Signal 2011; 4: Ra71
52. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467: 986-990
53. Luo Z, Dai Y, Zhang L, JiangC Li Z, Yang J et al. miR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma. Carcinogenesis 2012; 34: 415-425
54. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004; 14: 43-47 (Pubitemid 38167476)
55. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323 (Pubitemid 47355323)
56. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou A et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715 (Pubitemid 351636299)
57. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA 2010; 107: 18115-18120
58. Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK et al. A subpopulation of CD26 cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010; 6: 603-615
59. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601 (Pubitemid 351627379)
60. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-14914
61. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907 (Pubitemid 351482843)
62. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147-152
63. Feng R, Chen X, Yu Y, Su L, Yu B, Li J et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 2010; 298: 50-63
64. Hamada S, Satoh K, Fujibuchi W, Hirota M, Kanno A, Unno J et al. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res 2012; 10: 3-10
65. Sasahira T, Kurihara M, Bhawal UK, Ueda N, Shimomoto T, Yamamoto K et al. Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer 2012; 107: 700-706
66. Tome M, Lopez-Romero P, Albo C, Sepulveda JC, Fernandez-Gutierrez B, Dopazo A et al. miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ 2011; 18: 985-995
67. Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev 2011; 25: 226-231
68. Beck B, Driessens G, Goossens S, Youssef KK, Kuchnio A, Caauwe A et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011; 478: 399-403
69. Schepers AG, Snippert HJ, Stange DE, van Den Born M, van Es JH, van De Wetering M et al. Lineage tracing reveals Lgr5 stem cell activity in mouse intestinal adenomas. Science 2012; 337: 730-735
70. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008; 2: 333-344 (Pubitemid 351455242)
71. Merlos-Suarez A, Barriga FM, Jung P, Iglesias M, Cespedes MV, Rossell D et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011; 8: 511-524
72. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006; 13: 1238-1241 (Pubitemid 43905604)
73. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402 (Pubitemid 47506537)
74. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008; 3: E2428
75. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133 HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27: 1749-1758 (Pubitemid 351380265)
76. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009; 69: 1951-1957
77. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488: 522-526
78. Munoz P, Iliou MS, Esteller M. Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol 2012; 6: 620-636
79. Yu Z, Li Y, Fan H, Liu Z, Pestell RG. MiRNAs regulate stem cell self-renewal and differentiation. Front Genet 2012; 3: 191
80. Faber C, Horst D, Hlubek F, Kirchner T. Overexpression of Dicer predicts poor survival in colorectal cancer. Eur J Cancer 2011; 47: 1414-1419
81. Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, Schaerer L et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008; 68: 650-656 (Pubitemid 351206739)
82. Ghislin S, Deshayes F, Middendorp S, Boggetto N, Alcaide-Loridan C. PHF19 and Akt control the switch between proliferative and invasive states in melanoma. Cell Cycle 2012; 11: 1634-1645
83. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-Associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004; 23: 5748-5758 (Pubitemid 39093020)
84. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M et al. Nuclear signalling by tumour-Associated antigen EpCAM. Nat Cell Biol 2009; 11: 162-171
85. Gosens MJ, van Kempen LC, van De Velde CJ, van Krieken JH, Nagtegaal ID. Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol 2007; 20: 221-232 (Pubitemid 46422177)
86. Gorges TM, Tinhofer I, Drosch M, Rose L, Zollner TM, Krahn T et al. Circulating tumour cells escape from EpCAM-based detection Due to epithelial-Tomesenchymal transition. BMC Cancer 2012; 12: 178
87. Su YJ, Lai HM, Chang YW, Chen GY, Lee JL. Direct reprogramming of stem cell properties in colon cancer cells by CD44. Embo J 2011; 30: 3186-3199
88. Cho SH, Park YS, Kim HJ, Kin CH, Lim SW, Huh JW et al. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol 2012; 41: 211-218
89. Iliou MS, Lujambio A, Portela A, Brustle O, Koch P, Andersson-Vincent PH et al. Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer. Epigenetics 2011; 6: 1344-1353.